Free Trial

Insulet (PODD) Competitors

Insulet logo
$282.80 -5.49 (-1.90%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$282.79 -0.01 (-0.01%)
As of 02/21/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PODD vs. BDX, EW, IDXX, DXCM, RMD, STE, BAX, HOLX, GMED, and MASI

Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

Insulet vs.

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.

Becton, Dickinson and Company has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Insulet has a net margin of 21.22% compared to Becton, Dickinson and Company's net margin of 8.47%. Insulet's return on equity of 27.98% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company8.47% 15.74% 7.29%
Insulet 21.22%27.98%9.16%

Becton, Dickinson and Company currently has a consensus target price of $278.29, suggesting a potential upside of 22.30%. Insulet has a consensus target price of $289.06, suggesting a potential upside of 2.21%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Insulet
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Becton, Dickinson and Company had 15 more articles in the media than Insulet. MarketBeat recorded 48 mentions for Becton, Dickinson and Company and 33 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.51 beat Insulet's score of 0.96 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
42 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Insulet
13 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$20.18B3.24$1.71B$6.0237.80
Insulet$1.70B11.69$206.30M$5.8448.42

Insulet received 133 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 66.39% of users gave Insulet an outperform vote while only 62.43% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
600
62.43%
Underperform Votes
361
37.57%
InsuletOutperform Votes
733
66.39%
Underperform Votes
371
33.61%

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 18 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PODD vs. The Competition

MetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$19.84B$4.59B$5.80B$8.94B
Dividend YieldN/A39.91%4.78%3.85%
P/E Ratio48.4230.6126.4118.84
Price / Sales11.6949.73450.1476.68
Price / Cash74.7551.2344.0437.47
Price / Book26.966.577.634.64
Net Income$206.30M$90.13M$3.18B$245.69M
7 Day Performance0.80%-2.53%-1.82%-2.59%
1 Month Performance2.43%-2.42%0.22%-2.30%
1 Year Performance46.92%15.15%17.25%13.71%

Insulet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PODD
Insulet
4.3609 of 5 stars
$282.80
-1.9%
$289.06
+2.2%
+46.9%$20.22B$1.98B48.423,000Earnings Report
Analyst Forecast
News Coverage
Gap Down
High Trading Volume
BDX
Becton, Dickinson and Company
4.9252 of 5 stars
$224.89
-0.1%
$278.29
+23.7%
-7.3%$65.22B$20.18B37.3674,000Positive News
EW
Edwards Lifesciences
4.4114 of 5 stars
$76.23
+0.3%
$79.95
+4.9%
-15.5%$44.96B$6.00B11.0019,800Positive News
IDXX
IDEXX Laboratories
4.5297 of 5 stars
$444.53
-3.3%
$533.75
+20.1%
-18.4%$36.40B$3.90B41.6611,000Positive News
DXCM
DexCom
4.7438 of 5 stars
$89.07
+5.9%
$99.06
+11.2%
-23.7%$34.79B$3.62B53.349,600Positive News
High Trading Volume
RMD
ResMed
4.3687 of 5 stars
$232.93
-2.7%
$244.73
+5.1%
+28.5%$34.21B$4.69B27.509,980Analyst Revision
Positive News
STE
STERIS
4.7468 of 5 stars
$219.54
+0.1%
$258.75
+17.9%
-5.4%$21.57B$5.40B46.6118,179Positive News
BAX
Baxter International
4.1993 of 5 stars
$30.83
+0.7%
$39.44
+27.9%
-19.8%$15.74B$14.81B154.1660,000Earnings Report
Analyst Forecast
News Coverage
HOLX
Hologic
4.934 of 5 stars
$63.24
-0.6%
$85.77
+35.6%
-15.0%$14.27B$4.03B19.957,063
GMED
Globus Medical
4.8338 of 5 stars
$83.99
-0.2%
$96.91
+15.4%
+46.3%$11.44B$1.57B125.365,000Earnings Report
Analyst Forecast
News Coverage
MASI
Masimo
3.7241 of 5 stars
$181.31
+1.0%
$191.40
+5.6%
+28.7%$9.71B$2.05B125.045,200Analyst Revision
Positive News

Related Companies and Tools


This page (NASDAQ:PODD) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners